These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
414 related articles for article (PubMed ID: 34060252)
1. SPOP and OTUD7A Control EWS-FLI1 Protein Stability to Govern Ewing Sarcoma Growth. Su S; Chen J; Jiang Y; Wang Y; Vital T; Zhang J; Laggner C; Nguyen KT; Zhu Z; Prevatte AW; Barker NK; Herring LE; Davis IJ; Liu P Adv Sci (Weinh); 2021 Jul; 8(14):e2004846. PubMed ID: 34060252 [TBL] [Abstract][Full Text] [Related]
2. Ablation of EWS-FLI1 by USP9X inhibition suppresses cancer cell growth in Ewing sarcoma. Wang S; Huo X; Yang Y; Mo Y; Kollipara RK; Kittler R Cancer Lett; 2023 Jan; 552():215984. PubMed ID: 36330954 [TBL] [Abstract][Full Text] [Related]
3. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma. Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270 [TBL] [Abstract][Full Text] [Related]
4. Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening. Grohar PJ; Woldemichael GM; Griffin LB; Mendoza A; Chen QR; Yeung C; Currier DG; Davis S; Khanna C; Khan J; McMahon JB; Helman LJ J Natl Cancer Inst; 2011 Jun; 103(12):962-78. PubMed ID: 21653923 [TBL] [Abstract][Full Text] [Related]
5. EWS-FLI1 regulates a transcriptional program in cooperation with Foxq1 in mouse Ewing sarcoma. Shimizu R; Tanaka M; Tsutsumi S; Aburatani H; Yamazaki Y; Homme M; Kitagawa Y; Nakamura T Cancer Sci; 2018 Sep; 109(9):2907-2918. PubMed ID: 29945296 [TBL] [Abstract][Full Text] [Related]
6. High-throughput RNAi screen in Ewing sarcoma cells identifies leucine rich repeats and WD repeat domain containing 1 (LRWD1) as a regulator of EWS-FLI1 driven cell viability. He T; Surdez D; Rantala JK; Haapa-Paananen S; Ban J; Kauer M; Tomazou E; Fey V; Alonso J; Kovar H; Delattre O; Iljin K Gene; 2017 Jan; 596():137-146. PubMed ID: 27760381 [TBL] [Abstract][Full Text] [Related]
7. MiR-30a-5p connects EWS-FLI1 and CD99, two major therapeutic targets in Ewing tumor. Franzetti GA; Laud-Duval K; Bellanger D; Stern MH; Sastre-Garau X; Delattre O Oncogene; 2013 Aug; 32(33):3915-21. PubMed ID: 22986530 [TBL] [Abstract][Full Text] [Related]
8. The orphan nuclear receptor DAX1 is up-regulated by the EWS/FLI1 oncoprotein and is highly expressed in Ewing tumors. Mendiola M; Carrillo J; García E; Lalli E; Hernández T; de Alava E; Tirode F; Delattre O; García-Miguel P; López-Barea F; Pestaña A; Alonso J Int J Cancer; 2006 Mar; 118(6):1381-9. PubMed ID: 16206264 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of HDACs reduces Ewing sarcoma tumor growth through EWS-FLI1 protein destabilization. Pedot G; Marques JG; Ambühl PP; Wachtel M; Kasper S; Ngo QA; Niggli FK; Schäfer BW Neoplasia; 2022 May; 27():100784. PubMed ID: 35366465 [TBL] [Abstract][Full Text] [Related]
10. Suppression of FOXO1 is responsible for a growth regulatory repressive transcriptional sub-signature of EWS-FLI1 in Ewing sarcoma. Niedan S; Kauer M; Aryee DN; Kofler R; Schwentner R; Meier A; Pötschger U; Kontny U; Kovar H Oncogene; 2014 Jul; 33(30):3927-38. PubMed ID: 23995784 [TBL] [Abstract][Full Text] [Related]
11. Dual targeting of EWS-FLI1 activity and the associated DNA damage response with trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth. Grohar PJ; Segars LE; Yeung C; Pommier Y; D'Incalci M; Mendoza A; Helman LJ Clin Cancer Res; 2014 Mar; 20(5):1190-203. PubMed ID: 24277455 [TBL] [Abstract][Full Text] [Related]
14. iPSC-Derived Neoantigen-Specific CTL Therapy for Ewing Sarcoma. Ishii M; Ando J; Yamazaki S; Toyota T; Ohara K; Furukawa Y; Suehara Y; Nakanishi M; Nakashima K; Ohshima K; Nakauchi H; Ando M Cancer Immunol Res; 2021 Oct; 9(10):1175-1186. PubMed ID: 34385178 [TBL] [Abstract][Full Text] [Related]
15. EWS-FLI1 perturbs MRTFB/YAP-1/TEAD target gene regulation inhibiting cytoskeletal autoregulatory feedback in Ewing sarcoma. Katschnig AM; Kauer MO; Schwentner R; Tomazou EM; Mutz CN; Linder M; Sibilia M; Alonso J; Aryee DNT; Kovar H Oncogene; 2017 Oct; 36(43):5995-6005. PubMed ID: 28671673 [TBL] [Abstract][Full Text] [Related]
16. Junction region of EWS-FLI1 fusion protein has a dominant negative effect in Ewing's sarcoma in vitro. Jully B; Vijayalakshmi R; Gopal G; Sabitha K; Rajkumar T BMC Cancer; 2012 Nov; 12():513. PubMed ID: 23145994 [TBL] [Abstract][Full Text] [Related]
17. ETV6 dependency in Ewing sarcoma by antagonism of EWS-FLI1-mediated enhancer activation. Gao Y; He XY; Wu XS; Huang YH; Toneyan S; Ha T; Ipsaro JJ; Koo PK; Joshua-Tor L; Bailey KM; Egeblad M; Vakoc CR Nat Cell Biol; 2023 Feb; 25(2):298-308. PubMed ID: 36658219 [TBL] [Abstract][Full Text] [Related]
18. Combined experience of six independent laboratories attempting to create an Ewing sarcoma mouse model. Minas TZ; Surdez D; Javaheri T; Tanaka M; Howarth M; Kang HJ; Han J; Han ZY; Sax B; Kream BE; Hong SH; Çelik H; Tirode F; Tuckermann J; Toretsky JA; Kenner L; Kovar H; Lee S; Sweet-Cordero EA; Nakamura T; Moriggl R; Delattre O; Üren A Oncotarget; 2017 May; 8(21):34141-34163. PubMed ID: 27191748 [TBL] [Abstract][Full Text] [Related]
19. Lurbinectedin Inactivates the Ewing Sarcoma Oncoprotein EWS-FLI1 by Redistributing It within the Nucleus. Harlow ML; Maloney N; Roland J; Guillen Navarro MJ; Easton MK; Kitchen-Goosen SM; Boguslawski EA; Madaj ZB; Johnson BK; Bowman MJ; D'Incalci M; Winn ME; Turner L; Hostetter G; Galmarini CM; Aviles PM; Grohar PJ Cancer Res; 2016 Nov; 76(22):6657-6668. PubMed ID: 27697767 [TBL] [Abstract][Full Text] [Related]
20. Proteasomal Degradation of the EWS-FLI1 Fusion Protein Is Regulated by a Single Lysine Residue. Gierisch ME; Pfistner F; Lopez-Garcia LA; Harder L; Schäfer BW; Niggli FK J Biol Chem; 2016 Dec; 291(52):26922-26933. PubMed ID: 27875302 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]